Do analysts prefer DRCT or SLGL?

Sol-Gel Technologies has a consensus price target of $110.00, indicating a potential upside of 49.78%. Given Sol-Gel Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Sol-Gel Technologies is more favorable than Direct Digital. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Direct Digital 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Sol-Gel Technologies 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60

Sol-Gel Technologies (SLGL) Competitors

$73.44 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$73.67 +0.23 (+0.31%)

As of 06/12/2026 04:10 PM Eastern

Compare

SLGL vs. DRCT, MGTX, ANNX, TBPH, and ABUS

Should you buy Sol-Gel Technologies stock or one of its competitors? MarketBeat compares Sol-Gel Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sol-Gel Technologies include Direct Digital (DRCT), MeiraGTx (MGTX), Annexon (ANNX), Theravance Biopharma (TBPH), and Arbutus Biopharma (ABUS).

How does Sol-Gel Technologies compare to Direct Digital?

Direct Digital (NASDAQ:DRCT) and Sol-Gel Technologies (NASDAQ:SLGL) are related small-cap companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Direct Digital has a beta of 5.34, meaning that its share price is 434% more volatile than the broader market. Comparatively, Sol-Gel Technologies has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market.

In the previous week, Direct Digital and Direct Digital both had 2 articles in the media. Direct Digital's average media sentiment score of 1.43 beat Sol-Gel Technologies' score of 0.44 indicating that Direct Digital is being referred to more favorably in the media.

Company	Overall Sentiment
Direct Digital	Positive
Sol-Gel Technologies	Neutral

4.0% of Direct Digital shares are owned by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are owned by institutional investors. 25.6% of Direct Digital shares are owned by company insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Sol-Gel Technologies has lower revenue, but higher earnings than Direct Digital. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Direct Digital, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Direct Digital	$34.69M	0.06	-$18.95M	-$201.62	N/A
Sol-Gel Technologies	$19.39M	10.64	-$6.13M	-$0.34	N/A

Sol-Gel Technologies has a net margin of -5.66% compared to Direct Digital's net margin of -65.75%. Direct Digital's return on equity of 0.00% beat Sol-Gel Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Direct Digital	-65.75%	N/A	-59.57%
Sol-Gel Technologies	-5.66%	-3.17%	-2.58%

Sol-Gel Technologies has a consensus price target of $110.00, indicating a potential upside of 49.78%. Given Sol-Gel Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Sol-Gel Technologies is more favorable than Direct Digital.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Direct Digital	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Summary

Sol-Gel Technologies beats Direct Digital on 11 of the 16 factors compared between the two stocks.

How does Sol-Gel Technologies compare to MeiraGTx?

Sol-Gel Technologies (NASDAQ:SLGL) and MeiraGTx (NASDAQ:MGTX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.

Sol-Gel Technologies has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market. Comparatively, MeiraGTx has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market.

Sol-Gel Technologies presently has a consensus target price of $110.00, indicating a potential upside of 49.78%. MeiraGTx has a consensus target price of $25.83, indicating a potential upside of 169.38%. Given MeiraGTx's stronger consensus rating and higher probable upside, analysts clearly believe MeiraGTx is more favorable than Sol-Gel Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Sol-Gel Technologies has higher earnings, but lower revenue than MeiraGTx. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sol-Gel Technologies	$19.39M	10.64	-$6.13M	-$0.34	N/A
MeiraGTx	$81.39M	10.91	-$114.20M	-$1.48	N/A

In the previous week, Sol-Gel Technologies had 1 more articles in the media than MeiraGTx. MarketBeat recorded 2 mentions for Sol-Gel Technologies and 1 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 1.89 beat Sol-Gel Technologies' score of 0.44 indicating that MeiraGTx is being referred to more favorably in the news media.

Company	Overall Sentiment
Sol-Gel Technologies	Neutral
MeiraGTx	Very Positive

Sol-Gel Technologies has a net margin of -5.66% compared to MeiraGTx's net margin of -151.12%. Sol-Gel Technologies' return on equity of -3.17% beat MeiraGTx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sol-Gel Technologies	-5.66%	-3.17%	-2.58%
MeiraGTx	-151.12%	-1,065.47%	-54.96%

26.2% of Sol-Gel Technologies shares are held by institutional investors. Comparatively, 67.5% of MeiraGTx shares are held by institutional investors. 66.5% of Sol-Gel Technologies shares are held by company insiders. Comparatively, 7.4% of MeiraGTx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

MeiraGTx beats Sol-Gel Technologies on 9 of the 16 factors compared between the two stocks.

How does Sol-Gel Technologies compare to Annexon?

Sol-Gel Technologies (NASDAQ:SLGL) and Annexon (NASDAQ:ANNX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment.

In the previous week, Annexon had 3 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 5 mentions for Annexon and 2 mentions for Sol-Gel Technologies. Annexon's average media sentiment score of 0.97 beat Sol-Gel Technologies' score of 0.44 indicating that Annexon is being referred to more favorably in the news media.

Company	Overall Sentiment
Sol-Gel Technologies	Neutral
Annexon	Positive

Sol-Gel Technologies has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market. Comparatively, Annexon has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market.

Annexon has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -5.66%. Sol-Gel Technologies' return on equity of -3.17% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sol-Gel Technologies	-5.66%	-3.17%	-2.58%
Annexon	N/A	-101.19%	-75.99%

Sol-Gel Technologies presently has a consensus price target of $110.00, indicating a potential upside of 49.78%. Annexon has a consensus price target of $16.00, indicating a potential upside of 239.70%. Given Annexon's higher probable upside, analysts plainly believe Annexon is more favorable than Sol-Gel Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Annexon	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

26.2% of Sol-Gel Technologies shares are held by institutional investors. 66.5% of Sol-Gel Technologies shares are held by insiders. Comparatively, 10.3% of Annexon shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Sol-Gel Technologies has higher revenue and earnings than Annexon. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sol-Gel Technologies	$19.39M	10.64	-$6.13M	-$0.34	N/A
Annexon	N/A	N/A	-$206.69M	-$1.22	N/A

Summary

Sol-Gel Technologies beats Annexon on 9 of the 16 factors compared between the two stocks.

How does Sol-Gel Technologies compare to Theravance Biopharma?

Theravance Biopharma (NASDAQ:TBPH) and Sol-Gel Technologies (NASDAQ:SLGL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

In the previous week, Theravance Biopharma and Theravance Biopharma both had 2 articles in the media. Sol-Gel Technologies' average media sentiment score of 0.44 beat Theravance Biopharma's score of -0.06 indicating that Sol-Gel Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Theravance Biopharma	Neutral
Sol-Gel Technologies	Neutral

Theravance Biopharma presently has a consensus price target of $21.83, indicating a potential upside of 31.21%. Sol-Gel Technologies has a consensus price target of $110.00, indicating a potential upside of 49.78%. Given Sol-Gel Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Sol-Gel Technologies is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theravance Biopharma	0 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

99.1% of Theravance Biopharma shares are held by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are held by institutional investors. 7.7% of Theravance Biopharma shares are held by insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Theravance Biopharma has a beta of 0.17, indicating that its share price is 83% less volatile than the broader market. Comparatively, Sol-Gel Technologies has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market.

Theravance Biopharma has a net margin of 104.34% compared to Sol-Gel Technologies' net margin of -5.66%. Theravance Biopharma's return on equity of 18.84% beat Sol-Gel Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma	104.34%	18.84%	10.94%
Sol-Gel Technologies	-5.66%	-3.17%	-2.58%

Theravance Biopharma has higher revenue and earnings than Sol-Gel Technologies. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theravance Biopharma	$107.46M	7.98	$105.89M	$2.20	7.56
Sol-Gel Technologies	$19.39M	10.64	-$6.13M	-$0.34	N/A

Summary

Theravance Biopharma beats Sol-Gel Technologies on 8 of the 14 factors compared between the two stocks.

How does Sol-Gel Technologies compare to Arbutus Biopharma?

Arbutus Biopharma (NASDAQ:ABUS) and Sol-Gel Technologies (NASDAQ:SLGL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Sol-Gel Technologies has higher revenue and earnings than Arbutus Biopharma. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$14.08M	59.77	-$33.50M	$0.83	5.13
Sol-Gel Technologies	$19.39M	10.64	-$6.13M	-$0.34	N/A

Arbutus Biopharma presently has a consensus target price of $5.00, suggesting a potential upside of 17.37%. Sol-Gel Technologies has a consensus target price of $110.00, suggesting a potential upside of 49.78%. Given Sol-Gel Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Sol-Gel Technologies is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

In the previous week, Arbutus Biopharma and Arbutus Biopharma both had 2 articles in the media. Arbutus Biopharma's average media sentiment score of 0.93 beat Sol-Gel Technologies' score of 0.44 indicating that Arbutus Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Arbutus Biopharma	Positive
Sol-Gel Technologies	Neutral

43.8% of Arbutus Biopharma shares are held by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are held by institutional investors. 19.9% of Arbutus Biopharma shares are held by company insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Arbutus Biopharma has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market. Comparatively, Sol-Gel Technologies has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market.

Arbutus Biopharma has a net margin of 83.95% compared to Sol-Gel Technologies' net margin of -5.66%. Arbutus Biopharma's return on equity of 129.32% beat Sol-Gel Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	83.95%	129.32%	112.24%
Sol-Gel Technologies	-5.66%	-3.17%	-2.58%

Summary

Arbutus Biopharma and Sol-Gel Technologies tied by winning 8 of the 16 factors compared between the two stocks.

Get Sol-Gel Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLGL vs. The Competition

Export

Metric	Sol-Gel Technologies	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$206.37M	$5.88B	$6.74B	$12.07B
Dividend Yield	N/A	0.69%	2.67%	5.67%
P/E Ratio	-215.99	8.72	24.21	24.42
Price / Sales	10.64	21.47	512.04	109.94
Price / Cash	N/A	8.43	27.48	37.92
Price / Book	8.97	4.07	10.66	6.83
Net Income	-$6.13M	$99.67M	$3.57B	$337.67M
7 Day Performance	-8.20%	-0.15%	0.58%	1.17%
1 Month Performance	0.99%	2.58%	1.54%	3.16%
1 Year Performance	876.60%	116.73%	25.40%	30.58%

Sol-Gel Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLGL Sol-Gel Technologies	3.0162 of 5 stars	$73.44 flat	$110.00 +49.8%	+876.6%	$206.37M	$19.39M	N/A	50	Short Interest Increase Gap Up
DRCT Direct Digital	1.3078 of 5 stars	$2.88 -2.7%	N/A	-97.4%	$2.14M	$33.22M	N/A	60	Short Interest Decrease Gap Down
MGTX MeiraGTx	3.2485 of 5 stars	$9.21 +1.3%	$25.83 +180.5%	+44.6%	$852.94M	$81.39M	N/A	300	Gap Up
ANNX Annexon	3.8556 of 5 stars	$5.20 +1.6%	$16.00 +207.7%	+89.2%	$851.97M	N/A	N/A	60
TBPH Theravance Biopharma	2.6911 of 5 stars	$16.49 +1.2%	$21.83 +32.4%	+55.7%	$850.06M	$107.46M	7.50	110

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLGL) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sol-Gel Technologies (SLGL) Competitors

SLGL vs. DRCT, MGTX, ANNX, TBPH, and ABUS

How does Sol-Gel Technologies compare to Direct Digital?

Summary

How does Sol-Gel Technologies compare to MeiraGTx?

Summary

How does Sol-Gel Technologies compare to Annexon?

Summary

How does Sol-Gel Technologies compare to Theravance Biopharma?

Summary

How does Sol-Gel Technologies compare to Arbutus Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLGL vs. The Competition

Sol-Gel Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sol-Gel Technologies (SLGL) Competitors

SLGL vs. DRCT, MGTX, ANNX, TBPH, and ABUS

How does Sol-Gel Technologies compare to Direct Digital?

Which has more risk and volatility, DRCT or SLGL?

Does the media refer more to DRCT or SLGL?

Do institutionals & insiders believe in DRCT or SLGL?

Which has higher earnings and valuation, DRCT or SLGL?

Is DRCT or SLGL more profitable?

Do analysts prefer DRCT or SLGL?

Summary

How does Sol-Gel Technologies compare to MeiraGTx?

Which has more volatility and risk, SLGL or MGTX?

Do analysts prefer SLGL or MGTX?

Which has better earnings & valuation, SLGL or MGTX?

Does the media prefer SLGL or MGTX?

Is SLGL or MGTX more profitable?

Do insiders & institutionals believe in SLGL or MGTX?

Summary

How does Sol-Gel Technologies compare to Annexon?

Does the media prefer SLGL or ANNX?

Which has more risk and volatility, SLGL or ANNX?

Is SLGL or ANNX more profitable?

Do analysts rate SLGL or ANNX?

Do insiders and institutionals believe in SLGL or ANNX?

Which has better earnings and valuation, SLGL or ANNX?

Summary

How does Sol-Gel Technologies compare to Theravance Biopharma?

Does the media favor TBPH or SLGL?

Do analysts recommend TBPH or SLGL?

Do insiders & institutionals hold more shares of TBPH or SLGL?

Which has more risk & volatility, TBPH or SLGL?

Is TBPH or SLGL more profitable?

Which has better valuation and earnings, TBPH or SLGL?

Summary

How does Sol-Gel Technologies compare to Arbutus Biopharma?

Which has better earnings and valuation, ABUS or SLGL?

Do analysts prefer ABUS or SLGL?

Does the media favor ABUS or SLGL?

Do insiders and institutionals hold more shares of ABUS or SLGL?

Which has more risk & volatility, ABUS or SLGL?

Is ABUS or SLGL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLGL vs. The Competition

Sol-Gel Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools